EMERGING THERAPIES IN PRIMARY BILIARY CHOLANGITIS: OVERVIEW OF CLINICALTRIALS.GOV
Alorfi, N., Alourfi, M., Alsharif, S., Aljehani, M., Alsabban, A., Almatrafi, M., Zakri, Y., AlMahmoud, A., Ghunaiem, M., Almalki, R., Aljerary, I., Alkhattabi, A. (2024). EMERGING THERAPIES IN PRIMARY BILIARY CHOLANGITIS: OVERVIEW OF CLINICALTRIALS.GOV. EKB Journal Management System, 47(1), 629-638. doi: 10.21608/bfsa.2023.247640.1961
Nasser M Alorfi; Mansour Alourfi; Saeed Alsharif; Mohannad Abdulrahman Aljehani; Abdulmalik Mohammed Alsabban; Mohammad J Almatrafi; Ysear Abdulaziz Zakri; Abdullah AlMahmoud; Monther F Ghunaiem; Rami Ahmad Almalki; Ibrahim Smran Aljerary; Abdullah Alkhattabi. "EMERGING THERAPIES IN PRIMARY BILIARY CHOLANGITIS: OVERVIEW OF CLINICALTRIALS.GOV". EKB Journal Management System, 47, 1, 2024, 629-638. doi: 10.21608/bfsa.2023.247640.1961
Alorfi, N., Alourfi, M., Alsharif, S., Aljehani, M., Alsabban, A., Almatrafi, M., Zakri, Y., AlMahmoud, A., Ghunaiem, M., Almalki, R., Aljerary, I., Alkhattabi, A. (2024). 'EMERGING THERAPIES IN PRIMARY BILIARY CHOLANGITIS: OVERVIEW OF CLINICALTRIALS.GOV', EKB Journal Management System, 47(1), pp. 629-638. doi: 10.21608/bfsa.2023.247640.1961
Alorfi, N., Alourfi, M., Alsharif, S., Aljehani, M., Alsabban, A., Almatrafi, M., Zakri, Y., AlMahmoud, A., Ghunaiem, M., Almalki, R., Aljerary, I., Alkhattabi, A. EMERGING THERAPIES IN PRIMARY BILIARY CHOLANGITIS: OVERVIEW OF CLINICALTRIALS.GOV. EKB Journal Management System, 2024; 47(1): 629-638. doi: 10.21608/bfsa.2023.247640.1961

EMERGING THERAPIES IN PRIMARY BILIARY CHOLANGITIS: OVERVIEW OF CLINICALTRIALS.GOV

Bulletin of Pharmaceutical Sciences Assiut University
Article 42, Volume 47, Issue 1, June 2024, Page 629-638  XML PDF (771.15 K)
Document Type: Review Article
DOI: 10.21608/bfsa.2023.247640.1961
View on SCiNiTO View on SCiNiTO
Authors
Nasser M Alorfi email orcid 1; Mansour Alourfi2, 3; Saeed Alsharif4; Mohannad Abdulrahman Aljehani5; Abdulmalik Mohammed Alsabban6; Mohammad J Almatrafi6; Ysear Abdulaziz Zakri6; Abdullah AlMahmoud7; Monther F Ghunaiem8; Rami Ahmad Almalki9; Ibrahim Smran Aljerary9; Abdullah Alkhattabi3
1Pharmacology and Toxicology Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia
2Internal Medicine Department, King Faisal Medical City for Southern Region, Abha, Saudi Arabia
3Department of Gastroenterology, East Jeddah Hospital, Jeddah, Saudi Arabia
4Gastroenterology Department, Armed force Hospital of Southern Region, Khamis Mushait, Saudi Arabia
5Division of Gastroenterology, Department of Medicine, King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia
6Gastroenterology Section, Department of Medicine, King Abdulaziz Medical City, Jeddah, Saudi Arabia
7Gastroenterology Section, Internal Medicine Department, King Fahad Hospital, Jeddah, Saudi Arabia
8Gastroenterology Section, Department of Internal Medicine, Collage of Medicine, Taibah University, Almadinah Almuawwarah, Saudi Arabia
9Pharmaceutical care department, King Faisal Hospital, Makkah Cluster, Makkah, Saudi Arabia
Abstract
Abstract

Background: Primary biliary cholangitis (PBC) is an autoimmune disorder leading to different hepatic disorders. Progressive bile duct damage could result in cirrhosis. However, different clinical trials are undergone to test, evaluate and analyze t therapeutics used for management of PBC.

Aim: Identifying the emerging therapies in primary biliary cholangitis.

Methods: A comprehensive analysis of clinicaltrials.gov registry on and up to 7th November 2023. A list of included trials based on the review’s inclusion and exclusion criteria was further investigated.

Results: 156 clinical trials linked to primary biliary cholangitis were found. Twenty of them are completed with result. Almost twenty chemical formula and medications were tested. These medications targeted fibrotic pathways, immune modulation, Selective farnesoid X receptor (FXR) agonist, ileal bile acid transport inhibitor and bile acid metabolism.

Conclusion: Several promising medications were found for primary biliary cholangitis. These medications undergo different stages of trials to evaluate their tolerability, efficacy, and safety. Further investigations are extremely warranted.


Keywords
Primary Biliary Cholangitis; hepatology; Clinical Trials; therapeutics; metabolic disorder
Statistics
Article View: 250
PDF Download: 77